Profound Medical (TSE:PRN) Hits New 12-Month Low – Time to Sell?

Profound Medical Corp. (TSE:PRN)’s share price reached a new 52-week low during trading on Tuesday . The stock traded as low as C$9.62 and last traded at C$9.70, with a volume of 8305 shares. The stock had previously closed at C$9.97.

Analyst Upgrades and Downgrades

Separately, Raymond James upgraded Profound Medical to a “strong-buy” rating in a report on Saturday, November 9th.

Profound Medical Price Performance

The firm has a fifty day moving average price of C$10.65 and a two-hundred day moving average price of C$11.40. The stock has a market capitalization of C$232.07 million, a P/E ratio of -5.71 and a beta of 0.81. The company has a debt-to-equity ratio of 16.95, a quick ratio of 14.98 and a current ratio of 8.61.

Profound Medical (TSE:PRN) last released its quarterly earnings results on Thursday, November 7th. The company reported C($0.52) earnings per share for the quarter, missing the consensus estimate of C($0.42) by C($0.10). During the same quarter in the previous year, the company earned ($0.35) earnings per share. As a group, analysts expect that Profound Medical Corp. will post -1.9000001 EPS for the current fiscal year.

Insider Buying and Selling

In other Profound Medical news, Director Arun Menawat Dr. purchased 20,000 shares of the firm’s stock in a transaction on Tuesday, December 10th. The shares were acquired at an average cost of C$10.65 per share, with a total value of C$213,000.00. Also, Senior Officer Thomas Michael Tamberrino purchased 13,333 shares of the firm’s stock in a transaction on Tuesday, December 10th. The shares were acquired at an average cost of C$10.65 per share, for a total transaction of C$141,996.45. 8.62% of the stock is owned by insiders.

Profound Medical Company Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.